Ronald Lee Fleming

US Patent:

52415694, Aug 31, 1993

Filed:

Oct 2, 1990

Appl. No.:

7/592355

Inventors:

Ronald H. Fleming - Redwood City CA

Assignee:

Charles Evans & Associates - Redwood City CA

International Classification:

G21G 100

US Classification:

376159

Abstract:

Neutron activation analysis method and apparatus are disclosed wherein a sample in a vacuum chamber is irradiated with neutrons, the time when and energy of emitted gamma rays from a sample are detected, and delayed Beta-electrons emitted from the sample are detected and the positions of emission are imaged. Time coincidence between detected gamma rays and delayed Beta-electrons is determined and the location of elements on the sample is established from the detected coincidence and the image of the location on the sample where the delayed Beta-electrons were emitted.

US Patent:

20210363242, Nov 25, 2021

Filed:

Jan 15, 2019

Appl. No.:

16/962805

Inventors:

- Princeton NJ, US
Mark J. SELBY - San Francisco CA, US
Michelle Minhua HAN - Piedmont CA, US
Christine BEE - San Francisco CA, US
Andy X. DENG - San Mateo CA, US
Anan CHUNTHARAPAI - Daly City CA, US
Brigitte DEVAUX - Palo Alto CA, US
Huiming LI - Lexington MA, US
Paul O. SHEPPARD - Granite Falls WA, US
Alan J. KORMAN - Piedmont CA, US
Daniel F. ARDOUREL - Woodinville WA, US
Ekaterina DEYANOVA - Lawrenceville NJ, US
Richard Yu-Cheng HUANG - Bridgewater NJ, US
Guodong CHEN - East Brunswick NJ, US
Michelle Renne KUHNE - San Francisco CA, US
Hong-An TRUONG - San Francisco CA, US
Poliana PATAH - New Brunswick NJ, US
Jeffrey R. JACKSON - Schwenksville PA, US
Ronald A. FLEMING - Lawrenceville NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
A61K 39/395
A61P 35/00

Abstract:

This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.